Literature DB >> 10141711

The Cochrane Collaboration: the role of the UK Cochrane Centre in identifying the evidence.

C Lefebvre1.   

Abstract

This paper attempts to explain why systematic reviews of randomized controlled trials, based on as high a proportion as possible of the relevant studies, are so important in generating reliable information for evidence-based decision making within health care. The preparation, maintenance and dissemination of such reviews is the challenge which has been taken up by the Cochrane Collaboration. The first phase of data collection is the identification of relevant studies. Currently, bibliographic databases are inadequate for this task. MEDLINE searches identify on average only about half of the relevant studies, and until 1994 there were no suitable indexing terms in EMBASE to identify randomized controlled trials. Co-operation between the Cochrane Collaboration and both the National Library of Medicine and Elsevier, however, is already transforming this situation. From January 1994 a new indexing term has been added to EMBASE to help identify randomized controlled trials. From January 1995 a new indexing term will be added to MEDLINE to help identify controlled trials where the method of allocation to treatment or control cannot be described with certainty as being randomized. Also from January 1995 an additional 20,000 reports will be identifiable as randomized controlled trials in MEDLINE. Progress during the first 2 years of the Cochrane Collaboration has been encouraging, but much remains to be done if users of health services are to benefit from the evidence-based health care which they deserve.

Mesh:

Year:  1994        PMID: 10141711     DOI: 10.1046/j.1365-2532.1994.1140235.x

Source DB:  PubMed          Journal:  Health Libr Rev        ISSN: 0265-6647


  4 in total

1.  Identifying reports of controlled trials in the BMJ and the Lancet.

Authors:  S J McDonald; C Lefebvre; M J Clarke
Journal:  BMJ       Date:  1996-11-02

Review 2.  Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis.

Authors:  K McCaffery; R E Olver; M Franklin; S Mukhopadhyay
Journal:  Thorax       Date:  1999-05       Impact factor: 9.139

3.  Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks.

Authors:  S Mukhopadhyay; M Singh; J I Cater; S Ogston; M Franklin; R E Olver
Journal:  Thorax       Date:  1996-04       Impact factor: 9.139

4.  Systematic review of nebulized antibiotics in cystic fibrosis: evolution of protocol.

Authors:  S Mukhopadhyay; M Singh; S Ogston; G Ryan; R Smyth
Journal:  J R Soc Med       Date:  1998       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.